Retatrutide

Retatrutide (LY3437943) is an investigational once-weekly agonist of three receptors: GIP, GLP-1 and glucagon. It is being evaluated in phase 3 clinical trials and is not approved as a medicine anywhere.

Because demand is high and supply is unregulated, counterfeit and under-dosed products are common, so independent testing is essential.

Before you buy

• A lab report for this exact batch (a Certificate of Analysis)
• A batch number on the vial that matches the report
• A sealed vial of freeze-dried powder, stored cold and away from light as the label requires

Informational summary only, not medical advice. Read the safety guide and consult a qualified healthcare professional.